Enveric Biosciences, Inc.
ENVB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000890821
No open-market purchases or sales by Enveric Biosciences, Inc. insiders were filed in the last 90 days; 24 institutions reported holding it in 13F filings for Q2 2026, worth $736.8K in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Enveric Biosciences, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 31 | 27 | −4 |
| Shares | 11.0M | 9.31M | −1.64M (−15.0%) |
| Value | $3.61M | $1.99M | −$1.62M (−44.8%) |
New holders (6)
Institutions that held Enveric Biosciences, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 227,618 | $49.0K | 0.00% |
| Veritable, L.P. | 20,000 | $4.00K | 0.00% |
| HRT Financial LP | 13,698 | $2.00K | 0.00% |
| Two Sigma Advisers, LP | 10,400 | $2.00K | 0.00% |
| FMR LLC | 3 | $0 | 0.00% |
| Credit Suisse AG | 1 | $0 | 0.00% |
Sold out (10)
Institutions that held Enveric Biosciences, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Mirae Asset Global Investments Co., Ltd. | 286,267 | $94.0K |
| Susquehanna International Group, LLP | 176,363 | $58.0K |
| Price T Rowe Associates Inc | 107,500 | $35.0K |
| Citadel Advisors LLC | 58,332 | $20.0K |
| Boothbay Fund Management, LLC | 44,160 | $15.0K |
| Warberg Asset Management LLC | 45,000 | $15.0K |
| Citigroup Inc | 16,765 | $6.00K |
| JPMorgan Chase & Co | 11,419 | $4.00K |
| Integrated Wealth Concepts LLC | 10,801 | $4.00K |
| Advisor Group Holdings, Inc. | 4,000 | $1.00K |